Connie Celum

Adjunct Professor, Epidemiology
Professor, Global Health
Professor, Medicine - Allergy and Infectious Dis.


MD Medicine, University of California (San Francisco), 1984
MPH Epidemiology, University of Washington, 1989


Box 359927
University of Washington
Seattle, WA
University of Washington
Box 359927
Allergy and Infectious Diseases
Seattle, WA 98195

Research Interests

Dr. Celum's research currently focuses on HIV prevention and vaccine trials with the objective to find effective strategies to reduce HIV acquisition and transmission. She utilizes epidemiologic data on behavioral and biologic risk factors for HIV acquisition and transmission to identify potential intervention strategies and then to conduct randomized clinical trials to determine safety and efficacy of these interventions with biologic outcome measurements. Her current effort is focused on sexually transmitted diseases (STDs), particularly genital herpes, as co-factors for HIV acquisition and transmission and clinical trials of candidate HIV vaccines. First, she is investigating HSV-2 as a co-factor for HIV acquisition and transmission, through a large randomized trial of daily antivirals for HSV-2 suppression to determine whether HIV acquisition can be reduced by 50% among HIV-negative, HSV-2 seropositive women in two African sites, and among MSM in Peru and two US sites. Second, to determine the effect of genital herpes on HIV infectiousness, she is conducting a large multi-center trial of HSV-2 suppression among HIV-discordant couples in Africa and India. Third, she is studying the effect of HSV-2 on mucosal HIV shedding with a double-blind cross-over study of valacyclovir among HIV/HSV-2 co-infected men and women in Peru. Fourth, she is studying the prevalence, incidence and risk factors for HSV-1 and HSV-2 acquisition among high-risk men who have sex with men in a multi-center trial of a behavioral intervention (Project Explore). Fifth, as part of her interest in the evaluation of HIV vaccine trials, she is developing approaches to assess the effect of partially-effective HIV vaccines on viral set-point and disease progression, including a standardized approach to provision of antiretroviral therapy for breakthrough infections in phase III trials.

Dr. Celum has developed research clinical units in Seattle and Lima, Peru, to conduct epidemiologic studies and clinical trials of HIV prevention interventions and vaccines. In addition, she serves as the PI on two multi-center international clinical trials of HSV-2 suppression and HIV transmission with sites in Africa, India, and Latin America, which provide opportunities for graduate students interested in studying the epidemiology of STD and HIV infection

HIV prevention; microbicide; vaccine trials with the objective to find effective strategies to reduce HIV acquisition and transmission.

Recent Publications (PubMed)

Correlates of Adherence to Oral and Vaginal Pre-exposure Prophylaxis (PrEP) Among Adolescent Girls and Young Women (AGYW) Participating in the MTN-034/REACH Trial.
(2024 Jun 9)
AIDS Behav
Ngure K, Browne EN, Reddy K, Friedland BA, van der Straten A, Palanee-Phillips T, Nakalega R, Gati B, Kalule HN, Siziba B, Soto-Torres L, Nair G, Garcia M, Celum C, Roberts ST

Youth-friendly services was the magic: Experiences of adolescent girls and young women in the community PrEP study, South Africa.
(2024 Jan)
Glob Public Health 19(1): 2349918
Mudzingwa EK, de Vos L, Fynn L, Atujuna M, Katz IT, Hosek S, Celum C, Daniels J, Bekker LG, Medina-Marino A

Doxycycline post-exposure prophylaxis for sexually transmitted infections impacts the gut antimicrobial resistome.
(2024 Apr 17)
Res Sq
Langelier C, Chu V, Glascock A, Donnell D, Grabow C, Brown C, Ward R, Love C, Kalantar K, Cohen S, Cannon C, Woodworth M, Kelley C, Celum C, Luetkemeyer A

Exploring adolescent girls and young women's PrEP-user profiles: qualitative insights into differentiated PrEP delivery platform selection and engagement in Cape Town, South Africa.
(2024 May)
J Int AIDS Soc 27(5): e26254
Rousseau E, Sikkema KJ, Julies RF, Mazer K, O'Malley G, Heffron R, Morton JF, Johnson R, Celum C, Baeten JM, Bekker LG

Doxycycline as Postsexual Exposure Prophylaxis: Use, Acceptability, and Associated Sexual Health Behaviors Among a Multi-Site Sample of Clinical Trial Participants.
(2024 Apr)
AIDS Patient Care STDS 38(4): 155-167
Fredericksen RJ, Perkins R, Brown CE, Cannon C, Lopez C, Cohee A, Dombrowski JC, Cohen S, Malinski C, Powell M, Luetkemeyer AF, Celum C, Christopoulos K

Show complete publication list